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The  need  to keep  vaccines  cold  in  the  face  of high  ambient  temperatures  and  unreliable  access  to  electricity
is a challenge  that  limits  vaccine  coverage  in  low  and  middle-income  countries  (LMICs).  Greater  vaccine
thermostability  is  generally  touted  as  the  obvious  solution.  Despite  conventional  wisdom,  comprehensive
analysis  of  the  value  proposition  for increasing  vaccine  thermostability  has been  lacking.  Further,  while
signiﬁcant  investments  have  been  made  in  increasing  vaccine  thermostability  in  recent  years,  no  vaccine
products  have  been  commercialized  as  a result.  We  analyzed  the  value  proposition  for  increasing  vaccine
thermostability,  grounding  the  analysis  in  speciﬁc  vaccine  use  cases  (e.g.,  use  in  routine  immunization
[RI]  programs,  or in  campaigns)  and in  the broader  context  of cold  chain  technology  and  country  level
supply  chain  system  design.  The  results  were  often  surprising.  For  example,  cold  chain  costs  actually
represent  a relatively  small  fraction  of  total  vaccine  delivery  system  costs.  Further,  there  are  critical,
vaccine  use  case-speciﬁc  temporal  thresholds  that  need  to be overcome  for  signiﬁcant  beneﬁts  to  be
reaped  from  increasing  vaccine  thermostability.  We  present  a  number  of  recommendations  deriving from
this  analysis  that suggest  a rational  path  toward  unlocking  the  value  (maximizing  coverage,  minimizing
total  system  costs)  of  increased  vaccine  thermostability,  including:  (1)  the  full range  of  thermostability
of  existing  vaccines  should  be deﬁned  and  included  in  their labels;  (2)  for  new  vaccines,  thermostability
goals should  be addressed  up-front  at the level  of  the  target  product  proﬁle;  (3)  improving  cold  chain
infrastructure  and  supply  chain  system  design  is likely  to  have  the  largest  impact  on  total  system  costs
and coverage  in  the  short  term—and  will  inﬂuence  the  degree of  thermostability  required  in  the  future;
(4)  in the  long  term,  there  remains  value  in  monitoring  the emergence  of  disruptive  technologies  that
could  remove  the  entire  RI portfolio  out  of  the  cold  chain.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
While vaccines have been integral to the dramatically declin-
ng rates of infectious disease morbidity and mortality enjoyed
ver the course of the last century, the health beneﬁts of vaccines
ave not been shared equally across the globe. Since 2000, there
as been a concerted effort to realize the full, equitable public
∗ Corresponding author at: The Bill & Melinda Gates Foundation, P.O. Box 23350,
eattle, WA 98102, USA. Tel.: +1 206 709 3549.
E-mail address: chris.karp@gatesfoundation.org (C.L. Karp).
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ttp://dx.doi.org/10.1016/j.vaccine.2015.05.071
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
health impact of vaccines in the process of meeting the Millennium
Development Goals and the supporting goals of the Global Immu-
nization Vision and Strategy (GIVS) and Global Vaccine Action Plan
(GVAP) developed by WHO  and UNICEF [1–3]. Three fundamen-
tal goals underlie the GIVS and many country-level immunization
strategies: (a) increasing vaccine coverage: extending immuniza-
tion to all children; (b) increasing vaccine effectiveness: ensuring
that the vaccines delivered are optimally efﬁcacious and simple to
administer; and (c) minimizing the total system cost of immuniza-
tion programs. Signiﬁcant progress toward achieving these goals
has been made by Global Alliance for Vaccines and Immuniza-
tion (GAVI) Alliance Partners, including: an additional 440 million
children immunized since 2000, which stands to prevent some 6
million future deaths and avert $63 billion in potential illness costs;
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ore equitable, accelerated access to new, innovative vaccines; and
ubstantial reductions in vaccine prices [4–6].
Despite this, signiﬁcant challenges remain. Some 20 million
nfants in GAVI countries, representing 26% of the birth cohort,
till fail to receive all of their basic vaccines [7]. Further, the
ong-term ﬁnancial sustainability of immunization remains a
oncern. The total cost of delivering immunizations in GAVI
ountries was approximately $2.2 billion in 2012, mostly funded
hrough donors (Supplementary Information). With the continued
ncrease of birth cohort size, continued rollout and introduction
f new, more costly vaccines (rotavirus, pneumococcal conju-
ate [PCV] and human papillomavirus [HPV] vaccines) and the
equired investment in delivery systems to reach the remaining
nfants, the total cost of immunization programs is projected to
ncrease to close to $4 billion per year by 2020 (Supplementary
nformation).
The temperature sensitivity of current vaccines, and the atten-
ant need for a robust cold chain, suggests that improving vaccine
hermostability could impact all three of the above goals. Devel-
pment of fully thermostable vaccines could increase coverage by
nabling the stocking of vaccines at facilities that do not have cold
hain equipment (CCE) and by facilitating outreach. The develop-
ent of such vaccines might improve efﬁcacy by decreasing the
robability of administering vaccines whose efﬁcacy was  impaired
y heat and/or freeze exposure. Finally, total system costs could be
educed by decreasing vaccine wastage due to detected heat and
reeze exposures, by decreasing the cold chain footprint, and by
educing the overall requirements for the vaccine delivery supply
hain.
Unquestioned optimism about the value of increased vaccine
hermostability led the Bill & Melinda Gates Foundation (BMGF),
nd the global public health community in general, to make large
nvestments in improving vaccine thermostability. These invest-
ents have led to some beneﬁts, including the development (if
ot the deployment) of novel freeze protection technologies and
 gratifying move to better exploitation of the actual thermo-
tability of existing vaccines through label changes that allow
igration to controlled temperature chains (CTC) [8]. However, to
ate, these investments have failed to result in the development
nd deployment of any commercial vaccine product with improved
hermostability. We  believe the reasons for this failure are several,
ncluding: (a) lack of a systematic approach centered on the speciﬁc
se conditions of speciﬁc products; (b) lack of strategic alignment
etween projects and unmet public health needs, or by the needs
dentiﬁed by those involved directly in vaccine delivery; (c) direc-
ing funds to academic approaches to technology development that
ere neither designed to develop a speciﬁc vaccine product nor
nformed by an understanding of the end-to-end research, devel-
pment and launch costs and their relationship to the relative value
f particular vaccine products; (d) inability to overcome technical
hallenges; (e) lack of attention to vaccine development issues and
ndustry motivations and incentives; and (f) lack of understanding
f total systems costs, and the impact that speciﬁc interventions
ould have on such.
. Thermostability analytic process
An analysis was performed that was designed to better
eﬁne the potential beneﬁts of increased vaccine thermostabi-
ity. The guiding hypothesis was that the probability of success—of
mpact—would be substantially increased by systematic end-to-
nd analysis of the value proposition for the development of speciﬁc
echnological solutions to increasing the thermostability of spe-
iﬁc vaccines with speciﬁc use cases. This was done in the overall
ontext of considering three critical, interrelated elements: vaccineFig. 1. Interrelated elements impacting cold chain performance.
thermostability itself, CCE infrastructure, and country-level vaccine
supply system design (Fig. 1).
In order to ground the analysis, we focused on four high pri-
ority vaccines: pneumococcal conjugate, inactivated polio (IPV),
rotavirus, and pentavalent vaccines. These vaccines were cho-
sen because: (a) they are relatively expensive and represent and
increasing proportion of vaccine spending in LMIC; (b) they have
or will have an outsized footprint in the cold chain; (c) they have
high priority, given ongoing and/or imminent introductions; and
(d) there is the potential for rapid impact (versus vaccines in the
research and development pipeline that have not achieved proof
of concept in humans). The analysis was rooted in real use cases
including routine immunization and campaigns/special strategies,
and focused on both heat and freeze as sources of damage.
An upstream landscaping was performed to assess the techni-
cal feasibility, research and development costs, and timelines of
producing more thermostable vaccines. This involved generating
catalogs of vaccines, thermostable formulation technologies, and
attendant alternative administration system technologies where
appropriate. These catalogs were used to analyze the risk, timing
and potential beneﬁt of each vaccine-technology pair to judge the
probability of technical and regulatory success. Finally, candidate
vaccine-technology pairs were identiﬁed that could reduce cost per
dose and/or increase health impact.
In parallel, a corresponding downstream analysis was per-
formed to assess the potential incremental beneﬁt of the
development of speciﬁc, more thermostable vaccines on total sys-
tem costs, including effects on cost of goods, wastage, transport
costs, cold chain equipment costs and healthcare worker costs. A
model for the total end-to-end systems costs associated with deliv-
ering routine immunization vaccines was ﬁrst generated, building
on and integrating prior work from WHO, PATH, the Decade of
Vaccines and others (Figs. 2 and 3; Supplementary Information).
This model was then used to estimate the impact on the total sys-
tem costs for the candidate vaccine-technology pairs identiﬁed in
the upstream analysis. Integration of these work streams aimed
to create an end-to-end analytical framework, founded on vaccine
delivery needs and integrating vaccine discovery and development
considerations, in order to deﬁne the value proposition for speciﬁc
product development. The analysis focused heavily on economic
impact—a function of the data at hand. That said, the impact of
increased thermostability on coverage (e.g., ease of administration,
potential for multi-day outreach, potential for offering vaccines
at health posts without CCE), safety (e.g., delivery methods that
require no sharps), and efﬁcacy (e.g., impact of improved heat
stability and freeze protection on efﬁcacy) was  integrated, qualita-
tively, into the analysis. The ﬁndings of the analysis are presented
C.L. Karp et al. / Vaccine 33
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n three sections below: heat stability for vaccines used in routine
mmunization (RI), heat stability for vaccines used in campaigns
nd special strategies, and freeze protection. It should be noted
hat this analysis, although applied directly only to a small group
f vaccines, actually provided clarity across a much wider group of
accines and vaccine use cases.
.1. Heat stability for vaccines used in routine immunizationRoutine immunization in GAVI countries occurs continuously
hroughout the year, is mostly done in ﬁxed health posts or via
hort outreach, and usually involves the administration of several
accines together. Complete removal of all RI vaccines from the
ig. 3. Total end-to-end system cost model (extrapolated to 2020). The main driver of s
pend  guidance per child and countries’ ability to reach 90% of that spend guidance. 2Assu
Transport & supply chain labor costs are based on the HERMES model (see Supplementa
wnership values from PATH. (2015) 3471–3479 3473
cold chain would lead to signiﬁcant beneﬁts in terms of cover-
age and total system cost. The fact that storage of RI vaccines is
limited to health posts equipped with CCE forces some parents
to travel large distances to immunization points or, conversely,
requires that healthcare workers perform expensive outreach by
traveling to remote villages. Removal of RI vaccines from the cold
chain would enable storage at unequipped health posts and likely
lead to increased coverage. It would also facilitate ﬂexible use cases
for RI vaccines, facilitating outreach to hard-to-reach populations.
For some types of vaccines, such as live viral vaccines, thermosta-
bility could reduce the likelihood of lost potency and efﬁcacy when
exposed to high ambient temperatures. While most heat-damaged
vaccines are thought to be identiﬁed through the use of vaccine vial
monitors (VVM) and discarded, some are likely to slip through and
be administered. Thus, a fully thermostable portfolio of RI vaccines
might also have a positive impact on vaccine efﬁcacy. Finally, a fully
thermostable RI portfolio would likely provide a $125–150 mil-
lion reduction in total system costs per year across GAVI countries
(Fig. 4), driven by reductions in wastage (estimated at $15–40
million per year across GAVI countries, or 1–3% of total vaccine
expenditures [Supplementary Information]) along with reductions
in the cost of cold chain equipment (estimated at ∼$110 million per
year) [Supplementary Information]. However, fully capturing these
beneﬁts necessitates not just removal of almost all RI vaccines from
the cold chain, but—critically—the removal of these vaccines for
periods of time that are driven by the length of time vaccines typ-
ically spend at various levels of the country supply chain. Notably,
the ability to harvest major beneﬁts from increased thermostability
of RI vaccines is driven by speciﬁc temporal thresholds, as outlined
in Fig. 5 (see also Supplementary Information).Certain beneﬁts of thermostability can be achieved quite
rapidly. RI vaccine stability outside of the cold chain (at 40 ◦C)
for several days allows for reduced wastage and undetected loss
of immunogenicity as well as, importantly, facilitating ﬂexible
ystem cost is vaccine purchases, followed by health worker time. 1Based on WHO
mes rotavirus, HPV, PCV, & IPV vaccines have been rolled out to all GAVI countries.
ry Information). 4Based on demand segmentation for refrigerators and total cost of
3474 C.L. Karp et al. / Vaccine 33
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Fig. 4. Potential savings from fully stable RI vaccine portfolio: up to ∼$150 M/year.
Percentages represent percentage of 2020 total system cost. 1On a projected
2020 base. 2Assumes closed vial wastage could be reduced by 20–60% depend-
ing  on current VVM. Source: PATH Total Cost of Ownership working model
from author correspondence with Project Optimize, PATH; “Cold Chain Equip-
ment Manager,” Published January 2012, http://www.path.org/publications/detail.
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se cases such as use of RI vaccines in campaign and special
trategy settings. Such short-term thermostability also allows
impliﬁcation of outreach by eliminating the need to keep vaccines
ool during day trips to remote vaccination sites (although there
re logistical challenges in terms of avoiding vials being repeatedly
aken out of refrigerators and returned).
A critical, larger breakpoint occurs around two months (at
0 ◦C), which is the typical maximum amount of time a vaccine
ial spends at a health post before being used (Fig. 5). If RI vaccines
ere made to be thermostable for two months, CCE at health
osts could potentially be removed, saving cost and reducing
National
Regional
District
Health-
posts
Typic
resup
time
3 mon 
3 mon 
3 mon 
1 mon 
Common supply  chain  structure
ig. 5. Common vaccine supply chain structures: quantization of beneﬁts of thermostabi
ery  remote) will need up to 3 months, given 100% buffer stock policies; assumes facilit
ime  to 6–9 months through system changes (e.g., informed push, de-layering). Source: o
linton Health Access Initiative. (2015) 3471–3479
complexity. Vaccines could also be stocked in a broader set of
health posts, potentially increasing coverage.
The third large breakpoint occurs around 12–18 months (at
40 ◦C), which is the typical amount of time vaccines currently spend
across all levels of the supply chain in a standard 4-level sup-
ply system (Fig. 5). The actual amount of time is dependent on
how efﬁciently the system is run—with signiﬁcant investment in
redesigning and speeding up of supply chains, this could poten-
tially be brought down to 6–9 months in the future. Achieving this
length of thermostability for the entire RI portfolio would enable
removal of cold chain equipment at all levels of the supply chain,
and a fundamental re-design of the supply chain, for example by
merging with other supply chains. In turn, this would allow reap-
ing of the full beneﬁts of removing the RI portfolio from the country
supply chain listed above (Fig. 4).
To identify ways to reach these stability thresholds, our anal-
ysis investigated a wide range of technologies for each of the
four selected RI vaccines. These technologies included re-labeling
to better reﬂect the inherent stability of vaccines, re-formulation
with various excipients, diverse drying technologies, and novel
formulations (e.g., microspheres, nanoparticles, microcrystals, silk
proteins, and sugar glassiﬁcation). Currently, these RI vaccines are
far away from the required stability for removal from the cold
chain [9]. There is a potential path to achieving about 6-month sta-
bility with rotavirus vaccine and IPV within the next 5 years by
leveraging novel lyophilization techniques. It should, however, be
noted that the products of drying technologies are broadly disliked
by health care workers and discouraged by global policy-making
committees and LMIC vaccine programs due to complexity and
errors in reconstitution [10]. Such techniques will be very challeng-
ing to apply to PCV or pentavalent vaccines, due to the additional
complexity of these vaccines—the multivalency of these vaccines
being associated with an unavoidable “weakest link” problem in
which the thermostability of the vaccine is hostage to the least
thermostable component. While there are some emerging tech-
nologies that might achieve the desired stability for PCV and/or
pentavalent vaccines, these technologies are highly nascent and
speculative. Further, as there is no licensable correlate of protection
for pertussis vaccine, the regulatory path for a new thermostable
pentavalent vaccine might well involve clinical studies with an efﬁ-
cacy endpoint—a challenging and expensive proposition. Therefore,
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level & fundamental  re-
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t this point in time, there is no clear way to achieve the minimum
hreshold of 2 months with the full portfolio.
There is broader complexity at work here as well. As there are
ultiple manufacturers of each of these vaccines, technologies for
tability improvement would need to be made available to all man-
facturers or else we would run the risk of seriously constraining
ur vaccine supply base by limiting the availability of the desired
hermostable vaccine to a small set of suppliers with access to the
ovel process or technology. This would raise the bar considerably
or maintaining a robust and secure vaccine supply base. Looked
t in this light, the complexities involved in achieving sufﬁcient
hermostability across the RI vaccine portfolio appear substan-
ially greater than the complexities involved in improving supply
nd cold chains (vide infra), strongly suggesting that: (a) a major
ffort aimed at generating and applying the technologies needed
o remove all RI vaccines from the cold chain, either at the health
ost level or entirely, is hard to justify at this point; and (b) atten-
ion to improvements in the supply and cold chains is likely to have
reater impact, at least in the near to mid-term.
If thermostability sufﬁcient to remove the Expanded Program
n Immunization (EPI) RI vaccine portfolio from the cold chain is
ot achieved, what about removal of a subset thereof? The cold
hain would still need to be maintained, and it would be signiﬁ-
antly harder to capture the above potential beneﬁts. Cost savings
ould be minimal (Fig. 6). Two strategies could be imagined, nei-
her having clear value: (1) storing of a subset of vaccines outside of
CE at health posts: health posts equipped with CCE could store sta-
le RI vaccines at ambient temperature, while continuing to keep
eat sensitive vaccines in CCE. There would be limited savings from
eing able to downsize some CCE, however, because there is a large
xed cost component to CCE. It could also potentially relieve bot-
lenecks at national and regional levels, although these account for
 very small fraction of cold chain spend. Further, if drying is used as
n approach to increase thermostability, this must be balanced by
he fact that keeping vaccines and diluents in separate vials means
hat the total product is larger, heavier and less convenient to use.
2) Stocking a subset of vaccines at health posts with no CCE: an
Various small 
devices
(e.g.,  SDD, 
passive or 
thermoelectric):
Facilities: ~40k 
Demand/yr:  ~4k
2nd generation
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Grid ac
C
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ity
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26%
4%
6%
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13%
dirG-ffO Minimal
mains 
(<8 hours)
ig. 7. 2020 cold chain equipment market segmentation: evenly split between on-grid an
ncludes India. 2“Moderate mains”: at least 8 h per day, longest power cuts <48 h.detail.php?i=1569. Accessed July 2013 (extrapolated distribution of equipment for
six countries to rest from expert interviews); see Supplementary Fig. 1 for wastage
sources. CCE, cold chain equipment.
alternate strategy would be to bifurcate the RI system, with heat-
sensitive vaccines being stored only at health posts with CCE, and
heat-stable vaccines being stored at a larger set of health posts. This
could potentially lead to higher coverage for this subset of vaccines.
However, such a system is not attractive, being complex to man-
age and access (with different trips to different health posts being
needed to get the full complement of vaccines) and involving clear
increases in expense. While excursions would be eliminated for
2nd generation
ice-lined
refrigerator 
(IL R):
Facilities: ~67k 
Demand/yr: ~6.7k
cess
9%
Moderate mains
42%
sniam etaredoM 2
(8-22 hours)
Reliable
(>22 
hours)
d off-grid facilities. 1Based on baseline volume of 400 cc per fully immunized child;
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hose vaccines that were made stable, there is a risk of increasing
xcursions for non-stable vaccines due to added complexity of cold
hain management.
It is acknowledged that the above analysis may  not ﬁt with the
eneral intuition that any increase in vaccine thermostability is
ound to be desirable. Thermostability in the range of days to weeks
oes in fact always have the potential to decrease wastage as well
s allow for ﬂexible use cases. In this vein, RI vaccines ﬁnd impor-
ant use in campaign and outreach settings. There is thus clear value
ocumenting and exploiting the actual thermostability of existing
I vaccines. Further, while the beneﬁts of reformulating existing
I vaccines to increase thermostability to serve these purposes are
nlikely to outweigh the considerable costs involved in develop-
ent and re-approval, the value proposition is quite different for
ew vaccines. There is clear beneﬁt to ensuring that all high prior-
ty vaccines in development have their “early zone” (days to weeks)
hermostability maximized, and to ensuring that the degree of such
hermostability is clearly deﬁned and included in the label.
The results of our analysis question the value of a major invest-
ent effort aimed at the development of high risk, disruptive
echnologies that could obviate the need for signiﬁcant elements
f the cold chain across the full RI portfolio. Such an effort is difﬁ-
ult to justify at the present time with the available landscape of
echnologies and, given past experience, investing in technology
evelopment not tied to a speciﬁc product is not recommended.
However, we recognize that targeted investments will be crit-
cal for achieving long-term thermostability goals. With that in
ind, we recommend: (1) ensuring that labels for existing RI vac-
ines reﬂect their true thermostability in order to enable ﬂexible
se cases such as outreach and campaign use in speciﬁc geogra-
hies/situations. (2) Building and documenting heat stability into
he development path of new vaccines to decrease wastage and
nable ﬂexible use cases. This includes deﬁning—and potentially
roviding—the range of incentives that would encourage manu-
acturers to consider optimizing these aspects for priority vaccines
urrently in development. (3) Making seed investments in tech-
ologies with a high probability of technical and regulatory success
o get appropriate threshold increases in the thermostability of
peciﬁc RI vaccines. (4) Continuing to monitor the emergence of
isruptive technologies with a view to moving the RI portfolio to
reater heat stability when feasible. (5) Only limited investment
n reformulating existing products until there is a line of sight to
tabilization of the full RI portfolio.
.2. Heat stability for campaign and special strategy vaccines
The above analysis of thermostability issues with RI vaccines
as important implications for campaign and special strategy
accines—and here it is useful to note that the campaigns that
id the world of smallpox and rinderpest were done with highly
hermostable vaccines [11,12]. Vaccine campaigns (and special
trategy immunization platforms) usually only involve 1–2 vac-
ines at a time and are of limited length, typically from a few
ays to one week. Thus while extended thresholds of stability are
eeded before major impacts are expected from increasing RI vac-
ine thermostability, this is not the case for campaign vaccines.
s a result, better documentation and exploitation of the existing
hermostability of such vaccines—enabling vaccine use at ambient
emperatures in a controlled temperature chain (CTC)—can enable
he administration of longer campaigns without the need for cold
torage, thus making it easier to reach remote populations and
ncrease coverage. Further, increased stability and leveraging of
TC can reduce the administrative burden on campaign workers.
vidence from a CTC pilot in Benin suggested reductions in both
he administrative burden of health care workers as well as in cold
hain costs. A modeling effort based on a larger sample in Chad (2015) 3471–3479
suggested a 15% reduction in administrative burden as the result
of setting up a CTC, along with a 79% reduction in cold chain costs
[13].
To unlock the value inherent in CTC migration of these vaccines,
there is a need to deﬁne and create market incentives to make
CTC development attractive for vaccine manufacturers, to continue
pilots to change behavior by demonstrating the beneﬁts of CTC
migration. Close attention will need to be paid to two issues: (a)
the need for novel VVMs, as current VVMs are designed for vaccines
kept in the cold chain and measure cumulative heat exposure. Vac-
cines in the CTC will require both cumulative and threshold VVMs
because they will be handled outside of the cold chain. (b) The fact
that optimal value will only be harvested when the temperature
use range of the product label matches the actual thermostability
of the product.
In addition to being able to easily unlock the beneﬁts of
incremental increases in campaign vaccine thermostability, the dif-
ferences between RI and campaign style vaccine use cases outlined
above also suggest that, for campaign vaccines as opposed to RI
vaccines, there is likely to be considerable value in investing in the
reformulation of speciﬁc, single campaign vaccines for increased
thermostability. There is no need for the concerted development
of a full portfolio of campaign vaccines past a speciﬁc threshold of
thermostability in order for coverage and total system cost beneﬁts
to be unlocked.
2.3. Freeze protection
While in the cold chain, vaccines are frequently exposed
to freezing temperatures, both in storage and in transport
[14]. Although the real health impact of freezing on vaccine
efﬁcacy is unknown, it may  well be underappreciated. Pre-
clinical immunogenicity studies suggest that alum-adjuvanted
vaccines are especially sensitive to freezing-induced degradation
of immunogenicity (>80% reduction in some cases; unpublished
data from PATH Freeze Protection Lab). Simple, cheap technological
solutions—in the form of excipients with cryoprotective properties
that are already approved for human parenteral use—are available
[15].
For vaccines under development, the rational path forward is
clear: cryoprotection should be built into the development path-
way at the level of the TPP. As such, engagement and collaboration
with vaccine manufacturers on this topic should be a priority.
Secondly, freeze protection is a case where “retroﬁtting” existing
vaccines may  represent a high value. For example, if even 1% of PCV
were compromised by freezing, the cost of delivering ineffective
doses would cover the cost of re-formulation within a few years.
However, such retroﬁtting would depend on there being incentives
for manufacturers to pursue such reformulation (e.g., preferential
treatment by GAVI, and partnering to cover costs of reformulation
and regulatory submission). And ﬁnally, to justify these efforts, it
will likely be critical to generate compelling data on how often vac-
cine freezing takes place, and what the loss of immunogenicity due
to such freezing actually is.
2.4. Summary
Thermostability requirements and beneﬁts vary by vaccine use
case. The ability to harvest major beneﬁts from increased RI vac-
cine heat stability is driven by speciﬁc temporal thresholds that are
dependent, in turn, on the design of supply systems. Surprisingly,
cold chain costs actually represent a relatively small fraction of the
total system cost for RI vaccines—making it hard to justify large
increases in expenditures for improving vaccine thermostability in
order to provide savings on cold chain equipment expenditures.
While considerable savings could indeed be achieved if the entire
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I portfolio could be removed from the cold chain for the minimum
-month threshold, this is not possible with current technologies.
or the present, there is clear value in deﬁning the actual thermo-
tability of both RI and campaign vaccines and including these data
n their labels. There is also clear value in prospectively addressing
hermostability issues (both heat and freeze sensitivity) for new
accines at the level of the target product proﬁle (TPP)—particularly
or the temporal breakpoints described above. For campaign vac-
ines, enabling migration to CTC can provide substantial beneﬁts
uickly and at a relatively low cost.
. Cold chain equipment analytics
Given the current challenges for wringing signiﬁcant beneﬁts
rom increasing the thermostability of the RI portfolio, addressing
old chain challenges—at the level of CCE infrastructure and coun-
ry vaccine supply system design—appears to be a less risky and
ore cost-effective strategy to increase vaccine coverage, at least
n the short term. A more informed focus on delivery systems, and
peciﬁcally on the cold chain, should enable the community to
eet goals for increasing vaccine coverage while minimizing over-
ll costs. Historically, cold chain interventions have been partially
onstrained by lack of clear data on CCE performance. This has led
o countries, global bodies and suppliers making critical decisions
ased on anecdotal information. To address this, a diagnostic was
onducted to uncover key CCE challenges. The diagnostic included
nterviews with global experts on cold chain, health systems, and
ountry infrastructure, in-depth country research to understand
ealth system structure and evolution and to assess user needs,
xtensive modeling of facility catchment and electriﬁcation and
old chain inventory, and supplier research and assessment of the
conomics of key technologies.
This diagnostic revealed that ∼17% of facilities targeted for
CE are unequipped, that a further ∼17% of installed refrigera-
ors are non-functioning, and that much of the rest suffer from
igniﬁcant technology ﬂaws, including high operating costs and
oor temperature control [16]. Combatting these problems will
nvolve: improving the understanding of user needs (especially
ow these vary within and across countries); enhancing the man-
gement of suppliers, including providing clear TPPs; expanding
n-country expertise on how to set up and manage cold chain sys-
ems; and addressing the projected funding gap of $350 million
rom now to 2020 [17]. These issues are explored in greater detail
elow.
.1. Equipment needs and market segmentation
Additional cold chain funding will need to be targeted at spe-
iﬁc facility needs. Two major factors drive the need for a speciﬁc
ype of CCE at a health post: electrical grid access and required
efrigerator capacity. For the ﬁrst time, to our knowledge, detailed
n-country data on user needs and implications have been gathered
hrough country visits, health post observation and in-depth inter-
iews with EPI managers and health post healthcare workers. An
stimated 50% of target health posts are on-grid, with at least 8 h of
lectricity per day (Fig. 7). Based on current trends, this proportion
ill not change dramatically in the coming years.2 This segment of
he market is best addressed with ice-lined refrigerators. There has
2 Several large investments in electricity have been announced in sub-
aharan Africa (The White House, “Power Africa: Fact Sheet,” June 30,
013. http://www.whitehouse.gov/the-press-ofﬁce/2013/06/30/fact-sheet-power-
frica. Accessed July, 2014), but the focus is primarily on generation rather than
xpanded grid access, and most investments will anyway take 10+ years to bear
ruit (2015) 3471–3479 3477
been confusion as to the amount of holdover time (time for tem-
perature maintenance in the absence of energy input) required,
but the current analysis indicates that for this segment power cuts
very rarely exceed 48 h: ∼3 days holdover should be sufﬁcient for
the vast majority of on-grid health posts (Fig. 7). Some other critical
but relatively simple improvements will also be required for exist-
ing products (e.g., built-in voltage regulators to avoid compressor
burnout, and user-independent protection from freezing).
The ∼50% of health posts that remain off-grid (either fully
or functionally), have traditionally been serviced through gas-
powered absorption refrigerators or, more recently, solar battery
refrigerators. However both these technologies have proven to be
unreliable, and in the case of absorption refrigerators have large
operational costs for fuel [16]. Several new technology options are
emerging, including battery-free solar direct drives, passive devices
that can keep cool for up to 30 days with a single load of ice, and
thermoelectric devices that leverage the Peltier effect to create a
cooling device with no moving parts. The two latter technologies
are limited in capacity to below 15 L, but we estimate that about 60%
of functionally off-grid facilities will require 15 L or less [16].3 These
facilities are therefore good candidates for passive and thermoelec-
tric devices, whereas larger off-grid facilities are best served with
solar direct drives (although it would also be possible to service
all off-grid facilities with solar direct drives). A tailored approach
to facility needs could equip all target facilities with functioning,
optimal equipment, but requires closing the funding gap of $350 M
[17].
3.2. CCE supply-shaping interventions
Incentivizing the production of optimal CCE will be key to
improving performance and lowering cost. Recently, WHO, GAVI,
UNICEF and BMGF collaborated to create TPPs for each of the
key CCE technologies in order to establish design parameters and
costs for addressing market needs [18]. Several manufacturers have
expressed both willingness and ability to meet these TPPs. Ulti-
mately, the aim is for these TPPs to be worked into pre-qualiﬁcation
requirements.
Another important intervention to shape the supply of CCEs is to
work with manufacturers to guide the design and manufacturing of
new products to reduce prices. For example, we estimate that the
price for a typical solar direct drive refrigerator can be reduced sig-
niﬁcantly through a combination of increased scale and improved
product design. Such manufacturing collaborations will help ensure
facilities have affordable products that match their needs.
3.3. Country decision support
Countries vary widely in terms of their infrastructure, and there-
fore their CCE needs. For example, India mostly has large on-grid
health posts [19], whereas Tanzania is almost fully off-grid with
very small health posts. Therefore, it is critical to help countries
make nuanced decisions based on a robust analysis of their local
needs. This should involve creating a CCE inventory, assessing
current and future facility needs, evaluating and selecting vari-
ous equipment types, and applying for funding and procurement
support including ensuring appropriate systems and budgets for
installation and maintenance.Going forward, plans should be created and implemented for
targeted support to countries with the ability to shape the CCE
market, including India, Tanzania, Nigeria, Ethiopia, Uganda, DRC
3 Assumes a volume requirement of 400 cc per immunized child, which includes
actual vaccine volume as well as ancillary factors such as buffer stock, seasonal
variations, wastage, and packing efﬁciency.
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Fig. 8. Time vaccines spend within country before use. X-axis: months, Y-axis: % vaccines. Countries blinded for conﬁdentiality (all sub-Saharan). 1Time between entering
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nd Ghana. These countries represent 30–50% of demand for each
ajor CCE technology segment [16]. In addition, a lighter-touch
odel should be created for other countries, including easier
ccess to up-to-date technical information and clear tools to
valuate technologies and total system cost implications
.4. Funding and procurement
CCE is a relatively small portion of routine yearly immuniza-
ion costs (∼4% when vaccine costs are included [Supplementary
nformation]). Cost reduction, especially for newer improved tech-
ologies, is important to ensure that countries do not face distorted
ncentives. Currently, funding and procurement for CCE is very dis-
ointed, leading to high prices, lack of transparency, fragmented
essaging to suppliers, and limited ability to shape the market
nd inﬂuence country decisions. However, over 80% of funds come
rom donors [17], thereby presenting an opportunity to inﬂuence
ecision-making toward increased consolidation and transparency.
e estimate that an extra $650 million will be required from now to
020, assuming current procurement patterns continue, but here
s potential to reduce this gap to $350 million if market-shaping
nterventions are successful [17]. Going forward, the community
hould continue its efforts to deﬁne alternate funding and procure-
ent mechanisms to alleviate these issues, and to engage donors
o ﬁll the funding gap.
There is a clear continued need for CCE over the coming decade.
he cold chain today suffers from challenges that are relatively
ffordable to overcome, particularly when compared to the cost
f some of the thermostability changes discussed earlier. Thus a
etter understanding of facility needs and investment in products
hat meet them will be a crucial part of improving vaccine delivery
n the near future.
. Country vaccine supply designVaccine thermostability needs and CCE infrastructure needs
re ultimately grounded in the overall design of country immu-
ization supply systems. Most countries still rely on antiquated
- or 5-level supply chains that were designed in the 1960s andes.
1970s, and have not been thoroughly revisited since. These sys-
tems are frequently slow, burdensome and unreliable, and it often
takes a year or more from the time a vaccine enters the national
stores until it gets used (Figs. 5 and 8). This drives up the required
thresholds for thermostability, and also increases the necessary
cold chain capacity since large buffer stocks are kept at each
level.
The way that vaccines are delivered to lower levels of the sup-
ply chain provides a critical lever for change. In many countries,
replenishment of stocks typically takes place by health posts send-
ing workers to pick up vaccines from upper levels of the supply
chain. This is in contrast to some more innovative models where
the stocks are pushed down to lower levels of the supply chain
in a data-driven way  that takes into account existing stocks, typi-
cal use patterns, and estimated levels of wastage factors. Finally,
there is an opportunity to re-think the role of private parties
in the vaccine supply chain. For instance, using private distrib-
utors can help leverage existing channels and reduce the need
for additional public investment. As country systems improve, the
key temporal thresholds for vaccine thermostability might well
decrease.
5. Summary
These analyses of the interrelated elements of vaccine thermo-
stability, cold chain technology and country level supply system
design led to ﬁndings that were surprising (the rather small relative
cost of the cold chain—expected to decline further as equipment
reliability improves; the speciﬁc duration thresholds required to
unlock the beneﬁts of vaccine thermostability) as well as expected
(the value of migrating to CTC for campaign vaccines; the fact that
unlocking the value of increased thermostability for RI vaccines
is more complicated). Key recommendations, aimed at optimi-
zing the public health impact of vaccines and fulﬁlling the global
health equity agenda, that follow from these analyses include: (1)
the full thermostability of existing vaccines should be deﬁned and
included in their labels; (2) for new vaccines, thermostability goals
(including both heat and freezing stability) should be addressed
up-front at the level of the target product proﬁle; (3) improving
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old chain infrastructure and supply chain system design is likely
o have the largest impact on total system costs and coverage in the
hort term—and will inﬂuence the degree of vaccine thermostabi-
ity required in the future; (4) in the long term, there remains value
n monitoring the emergence of disruptive technologies that could
emove the entire RI portfolio out of the cold chain.
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